Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Endocrine and neuroendocrine tumours

2419 - A phase II trial of palbociclib in metastatic grade 1/2 pancreatic neuroendocrine tumors: the PALBONET study on behalf of the Spanish Taskforce Group of Neuroendocrine Tumors (GETNE)


10 Sep 2017


Endocrine and neuroendocrine tumours


Enrique Grande Pulido


Annals of Oncology (2017) 28 (suppl_5): v142-v157. 10.1093/annonc/mdx368


E. Grande Pulido1, A. Teule2, T. Alonso-Gordoa1, P. Jiménez-Fonseca3, M. Benavent4, J. Capdevila5, A. Custodio6, R. Vera7, J. Munarriz8, A. La Casta-Muñoa9, R. Garcia-Carbonero10

Author affiliations

  • 1 Medical Oncology, Hospital Universitario Ramon y Cajal, 28031 - Madrid/ES
  • 2 Medical Oncology, ICO Belvitge, 08026 - Barcelona/ES
  • 3 Medical Oncology, H. U. Central de Asturias, 33011 - Oviedo/ES
  • 4 Medical Oncology, H. U. Virgen del Rpcío, 41013 - Sevilla/ES
  • 5 Gastrointestinal And Endocrine Tumor Unit, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 6 Medical Oncology, Hospital Universitario la Paz, 28046 - Madrid/ES
  • 7 Medical Oncology, Hospital de Navarra, 31008 - Pamplona/ES
  • 8 Medical Oncology, Hospital General de Castellón, 12004 - Castellón/ES
  • 9 Medical Oncology, H. U. Donostia, 20014 - San Sebastian/ES
  • 10 Medical Oncology Department, University Hospital 12 De Octubre, 28041 - Madrid/ES


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2419


Overexpression or amplification of cell cycle regulators like cyclin-dependent kinase-4 (Cdk-4), phospho-Rb1, or cyclin D1 are observed in 58%, 68%, and 68% pancreatic neuroendocrine tumors (pNETs), respectively. Moreover, these alterations correlate with a more aggressive behavior. Palbociclib targets Cdk-4/6 and has shown in vitro activity in pNETs cell lines overexpressing Cdk-4.


In this non-randomized, open-label, phase II study, patients (pts) with metastatic grade (G) 1/2 pNETs were recruited from 10 centres belonging to the Spanish Taskforce Group of NETS (GETNE). Palbociclib 125 mg was given once daily for 21 of 28 days until disease progression (DP) or unacceptable toxicity. The initial planned recruitment was 21 patients based on a 2-stage Simon’s phase II design, where palbociclib would be considered inactive if 


21 pts were included. One pt withdrew from the study due to clinical deterioration after < 1 month (m). 54% were males, mean age was 54 years (range: 33-66), and 67% had received > 3 previous lines of therapy (23.8% pazopanib; 80.9% sunitinib; 47.6% everolimus) beside somatostatin analogs. 20 pts were evaluable for ORR with a median follow up of 10m (4.23-12.43). No responses (0%) were observed; 11 (55%) pts had stable disease and 6 of them lasted more than 6m; 7 (35%) pts had progression as best response. 1 pt had tumor shrinkage of 8%. Median PFS was 1.9m (IC95% 0 - 13). Median OS was 16.6m (IC95% 9.3 – 23.9). Most frequent toxicities of any grade were: asthenia (16.2%), diarrhea (6.4%), abdominal pain (4.7%), nausea (4.3%) and neutropenia (11.5%). 5 pts developed G3-4 neutropenia (1 case of febrile neutropenia) and 2 pts G3-4 thrombocitopenia.


Lack of activity was observed with palbociclib in 21 molecularly unselected and heavily pretreated patients with advanced G1/2 pNETs. Translational studies correlating activity with molecular tumor markers and Ki67 proliferation index are ongoing.

Clinical trial identification

EudraCT: 2014-003924-34

Legal entity responsible for the study

GETNE (Spanish Taskforce Group for Neuroendorine Tumors)




E. Grande Pulido: Advisor for Ipsen, Pfizer, Lexicon. Scientific lectures for Pfizer and Ipsen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.